Evaluation of combined fibroblast growth factor-2 and moderate hypothermia therapy in traumatically brain injured rats

Both the exogenous administration of fibroblast growth factor-2 (FGF-2) or the induction of moderate hypothermia have been shown to attenuate histopathology and improve functional outcome after traumatic brain injury (TBI). Since combined therapeutic strategies may be more beneficial than single therapies, we examined the potential synergistic effect of FGF-2 combined with moderate hypothermia treatment induced 10 min after TBI on functional and histological outcome following controlled cortical impact (CCI) injury. Fifty male Sprague-Dawley rats were randomized to one sham and four CCI treatment groups: Sham+vehicle (VEH); FGF-2 (45 microg/kg/h for 3 h i.v.)+Normothermia (37+/-0.5 degrees C); FGF-2+Hypothermia (32+/-0.5 degrees C for 3 h); VEH+Norm; VEH+Hypo. Vestibulomotor performance on the beam balance and beam-walk (BW) tasks on post-operative days 1-5 and spatial memory acquisition in the Morris water maze (MWM) on days 14-18 were assessed. After 4 weeks survival, histological evaluations (CA(1) and CA(3) cell counts and lesion volume) were performed. MWM performance improved in all treatment groups, but combined treatment was not more efficacious than either alone. The FGF-2+Hypo group performed significantly better than the other injured treatment groups in the BW task. Lastly, no significant group differences in beam balance or histological outcome were observed. These data suggest a suboptimal and incomplete synergy of combined FGF-2 and hypothermia treatment. These data may indicate that either our dose of FGF-2 or combination therapy was not optimized in our model.     

Cross-cultural adaptation and validation of the Korean fibromyalgia impact questionnaire in women patients with fibromyalgia for clinical research

Our aim was to translate and cross-culturally adapt the fibromyalgia impact questionnaire into Korean (KFIQ), and then evaluate its reliability and validity. The FIQ was translated into Korean by three translators and then independently translated back into English by three different translators. A total of 62 women patients with fibromyalgia (FM) were studied for the psychometric properties of the KFIQ. The mean age of the patients was 47.1 (25-73) years, and all were female. The mean KFIQ score was 48.3 (17-91), and the mean Korean health assessment questionnaire (KHAQ) score was 0.4 (0-1.7). The test-retest reliability of the KFIQ yielded an intraclass correlation coefficient of 0.85 (0.53-0.96). For the construct validity, the Spearman rank correlations of KFIQ with patient global assessments using visual analog scale (pain, 0.58; morning stiffness, 0.45; fatigue, 0.48; depression, 0.43; anxiety, 0.56; global well-being, 0.46; disease severity, 0.49; impact on life, 0.51), KHAQ (0.44), and tender points (0.60) were high and statistically significant. The KFIQ might be a reliable and valid instrument for measuring health status and physical functioning in Korean women patients with FM, but needs further study.     

现金卫生支出贫困影响的分析方法研究

现金卫生支出的贫困影响方法研究是卫生领域公平性系列研究的重要组成部分。在借鉴国际研究成果的基础上，结合我国实际情况对其分析方法进行探索性研究，旨在从卫生筹资公平性角度，详细阐述现金卫生支出对贫困影响研究的分析方法和政策意义。     

本量利分析法在购置大型医疗设备中的应用

尝试运用成本-数量-利润分析法,从效益评估的角度对医院大型设备购置进行经济可行性分析。此方法可以帮助医院管理者选择合理的购买方案,控制投资成本,规划目标效益。     

医疗机构在结核病控制工作中的作用与影响

目的分析湖南省医疗机构肺结核病例转诊和结核病防治机构进行病例追踪后诊断情况,评价医疗机构在结核病控制工作中的作用和对全省结核病控制工作的影响。方法对2005年湖南省中国结核病控制工作月报表数据进行统计,分析医疗机构转诊到位病例中,不同类型肺结核病例报告数和构成比、结核病防治机构病例追踪到位率、不同类型追踪到位病例中肺结核病例诊断情况。结果2005年全省医疗机构报告肺结核病例24145例,除去辖区外和住院病例外,转诊到结核病防治机构9534例(48.8%),其中涂阳病例转诊到位率最高,占同类病例的63.5%,菌阴病例和未痰检病例分别占同类病例的42.4%和48.2%。结核病防治机构对未到位的病例进行追踪后到位5086例,总到位率为60.6%。在追踪到位的病例中,发现涂阳病例1419例(27.9%)和菌阴病例1817例(35.7%)。追踪到位的病例中经进一步检查属于非结核排除病例为29.2%,其中医疗机构报告的未痰检病例中属于非结核排除病例占34.6%。结论做好医疗机构肺结核病例的诊断、报告和转诊工作,对全省结核病控制工作将产生很大的社会效益和经济效益。应不断加强医疗机构和结核病防治机构的合作,促进全省结核病控制工作的持续发展。     

基于健康寿命损失的事故伤残间接损失统计

事故一旦发生,往往造成人员伤亡和财产损失,事故伤亡不仅导致经济损失,而且导致人员健康寿命的损失。该文首次应用DALY(伤残调整寿命年)来计算2005年我国工矿商贸企业伤亡事故导致的伤残寿命损失,基于国家公布的2005年我国工矿商贸企业事故的基础数据,计算2005年因事故伤亡导致的健康寿命损失至少有3651862人年,折合成静态经济损失约878亿元。通过计算健康寿命损失可以从一个全新的角度发现事故所造成人员伤亡引起的间接损失,为全面分析事故损失,进一步完善事故人员赔偿提供了科学依据。     

Genotoxicity studies of glycidol fatty acid ester (glycidol linoleate) and glycidol

Glycidol fatty acid esters (GEs) are found in refined edible oils. Safety concerns have been alleged due to the possible release of glycidol (G), an animal carcinogen.     

The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance

Abstract

Objectives: Potential opportunities and challenges of predictive genetic risk classification of healthy persons are currently discussed. However, the budgetary impact of rising demand is uncertain. This project aims to evaluate budgetary consequences of predictive genetic risk classification for statutory health insurance in Germany.

Methods: A Markov model was developed in the form of a cohort simulation. It analyzes a population of female relatives of hereditary breast cancer patients. Mutation carriers are offered intensified screening, women with a BRCA1 or BRCA2 mutation can decide on prophylactic mastectomy and/or ovarectomy. The model considers the following scenarios: (a) steady demand for predictive genetic testing, and (b) rising demand. Most input parameters are based on data of the German Consortium for Hereditary Breast and Ovarian Cancer. The model contains 49 health states, starts in 2015, and runs for 10 years. Prices were evaluated from the perspective of statutory health insurance.

Results: Steady demand leads to an expenditure of €49.8 million during the 10-year period. Rising demands lead to additional expenses of €125.5 million. The model reveals the genetic analysis to be the main cost driver while cost savings in treatment costs of breast and ovarian cancer are indicated.

Conclusions: The results contribute to close the knowledge gap concerning the budgetary consequences due to genetic risk classification. A rising demand leads to additional costs especially due to costs for genetic analysis. The model indicates budget shifts with cost savings due to breast and ovarian cancer treatment in the scenario of rising demands.